Cadence Neuroscience, a Redmond, Wash.-based developer of a novel neuromodulation therapy, secured $15m in Series A financing.
The round was led by Jazz Venture Partners, with participation from Mayo Clinical Ventures, Mayo Benefactors Innovation Fund, and the Epilepsy Foundation of America (EFA). In conjunction with the funding, John F. Harris and Andrew Firlik, M.D., of Jazz Venture Partners joined Cadence Neuroscience’s board of directors.
The company will use the funds to develop the technology, conduct clinical studies, and pursue FDA approval.
Founded in 2017 by Kent Leyde, Chief Executive Officer, Cadence is an early-stage company developing new medical device therapies for the treatment of epilepsy and other neurological disorders. Its core technology has been developed at Mayo Clinic and is under clinical evaluation.
The therapy, which utilizes chronic subthreshold cortical stimulation to modulate EEG biomarkers associated with epilepsy to reduce or eliminate seizures, was developed by a Mayo Clinic, Rochester campus Neurology and Neurosurgery team led by Gregory Worrell M.D., Ph.D., Mathew Stead M.D. Ph.D., Brian Lundstrom M.D. Ph.D., Ben Brinkmann Ph.D., and Jamie VanGompel, M.D.